NEW YORK, May 15, 2024 /PRNewswire/ -- Mason Capital
Management LLC, a Delaware limited
liability company ("Mason Capital"), announced today that it has
commenced a tender offer (the "Tender Offer") for any and all the
outstanding ADSs and Ordinary Shares in Forward Pharma A/S (the
"Company") for a purchase price of $437.00 per ADS or 0.76
DKK per Ordinary Share.
The Tender Offer is scheduled to expire at 5:00 p.m., Eastern Standard Time, on June 12, 2024 (unless extended or earlier
terminated with respect to a Tender Offer, the "Expiration Date").
The Tender Offer is being made pursuant to an Offer to Purchase
dated May 14, 2024 (the "Offer to
Purchase") and, with respect to the ADSs, a related Letter of
Transmittal, dated May 14, 2024 or,
with respect to the Ordinary Shares, a related form of Share
Transfer Note, dated May 14, 2024
(together, the "Tender Offer Materials"), which set forth a more
detailed description of the Tender Offer, including the terms and
conditions of the Tender Offer. Holders of ADSs and Ordinary Shares
are urged to carefully read the Tender Offer Materials before
making any decisions with respect to the Tender Offer. Copies of
the Tender Offer Materials will be provided to Holders of ADSs or
Ordinary Shares upon request by contacting MacKenzie Partners at
800-322-2885 or tenderoffer@mackenziepartners.com.
Subject to all conditions to the Tender Offer having been
satisfied or waived by Mason Capital, Mason Capital will purchase
ADSs and Ordinary Shares that have been validly tendered or
purchased by the Expiration Date no later than promptly following
the Expiration Date. ADSs and Ordinary Shares tendered into or
purchased pursuant to the Tender Offer will not be subject to
withdrawal from the Tender Offer and Mason Capital may, at its
option, purchase ADSs or Ordinary Shares validly tendered on one or
more dates at any time upon the satisfaction or waiver of all the
conditions to the Tender Offer described in the Tender Offer
Materials.
Mason Capital is making the Tender Offer only by, and pursuant
to, the terms of the Tender Offer Materials. Mason Capital does not
make any recommendations as to whether holders of ADSs or Ordinary
Shares should tender or refrain from tendering their ADSs or
Ordinary Shares. Holders must make their own decision as to whether
to participate in the Tender Offer and, if so, the amount of ADSs
or Ordinary Shares to tender or purchase. The Tender Offer is not
being made to holders of ADSs or Ordinary Shares in any
jurisdiction in which the making or acceptance thereof would not be
in compliance with the securities, blue sky or other laws of such
jurisdiction.
This press release does not constitute an offer to purchase
securities or a solicitation of an offer to sell any securities or
an offer to sell or the solicitation of an offer to purchase any
new securities, nor does it constitute an offer or solicitation in
any jurisdiction in which such offer or solicitation is unlawful.
Capitalized terms used in this press release but not otherwise
defined herein have the meanings assigned to them in the Tender
Offer Materials.
About Mason Capital
Mason Capital is a global event driven hedge fund founded in
July 2000 by Ken Garschina and Mike
Martino. Assets under management are $1.37 billion as of December 31, 2023. Mason Capital has an absolute
return focus and seeks to generate consistent positive returns in
any market environment.
View original
content:https://www.prnewswire.co.uk/news-releases/mason-capital-announces-tender-offer-for-any-and-all-of-i-the-outstanding-american-depositary-shares-the-adss-each-representing-4-000-ordinary-shares-nominal-value-0-01-dkk-of-forward-pharma-as-the-ordinary-shares-for-302145617.html